# Regression of Fatty Heart by Valsartan Therapy

> **NCT00745953** · PHASE4 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Metabolic Syndrome
- Lipotoxicity

## Interventions

- **DRUG:** Valsartan
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00745953
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-08
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00745953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00745953, "Regression of Fatty Heart by Valsartan Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00745953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*